Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement".
Biocon Limited Press Release Dec 23 2025
Filed with NSE · · 3 pages · English
Release
Earlier from Biocon
- Press Release Dec 17 2025
- Press Release Dec 15 2025
- Press Release Dec 13 2025
- Press Release Dec 11 2025
- Press Release Dec 06 2025
Later from Biocon
- Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference
- Press Release Jan 06 2026
- Biocon Limited Press Release Jan 15 2026
- Biocon Limited Press Release Jan 28 2026
- Press Release Feb 07 2026
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon